B&L enters the field of angiogenesis inhibition

Article

In a bid to enter the growing area of angiogenesis inhibition, Bausch & Lomb has announced the formation of two collaborations, both involving they licensing of anti-angiogenesis compounds for possible ophthalmic use.

In a bid to enter the growing area of angiogenesis inhibition, Bausch & Lomb has announced the formation of two collaborations, both involving they licensing of anti-angiogenesis compounds for possible ophthalmic use.

PTC Therapeutics has entered into an exclusive option agreement with the New York-based firm to develop therapeutic anti-angiogenesis candidates through PTC's proprietary screening technology GEMS (Gene Expression Modulation by Small Molecules). The aim of the collaboration is to develop compounds for ocular neovascularization including macular degeneration.

In a separate agreement, B&L has signed a deal with Pennsylvania-based firm Cephalon for the development, marketing and sale of ophthalmic products containing small-molecule angiogenesis inhibitors. Under the terms of this agreement, B&L will be responsible for preclinical and clinical development of compounds for ophthalmic use, will make a milestone payment to Cephalon upon regulatory acceptance of a New Drug Application, and will pay royalties based on product sales.

Advanced Medical Optics (AMO) has accelerated its rationalization and repositioning designed to enhance its position in the refractive surgical market. Originally planned for completion by the latter half of 2006, the reorganization reached its conclusion at the end of 2005.

The objectives of the reshuffle were to dispose of non-core cataract and eye-care products and eliminate non-core assets to allow the company to increase investment and growth in its refractive surgery business.

Since AMO was spun off from Allergan in 2002, the medical device company has acquired Pfizer Ophthalmics and VISX, whilst entering into many strategic alliances and expanding R&D investment and manufacturing capabilities.

With the latest move, AMO is now turning its attention to expanding markets within the industry and increasing its focus on R&D investment and utilization of resources on the big growth drivers, whilst better leveraging its well-established suite of cataract, refractive and eye care brands.

AMO expands presence in UK

The UK vision care company Optical Express has agreed to install Advanced Medical Optics' (AMO) recently approved VISX Star S4 IR excimer laser system for refractive surgery procedures.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.